Radiation Therapy with Nedaplatin and 5-FU for Recurrent Esophageal Cancer
Author Information
Author(s): Jingu Keiichi, Nemoto Kenji, Matsushita Haruo, Takahashi Chiaki, Ogawa Yoshihiro, Sugawara Toshiyuki, Nakata Eiko, Takai Yoshihiro, Yamada Shogo
Primary Institution: Tohoku University School of Medicine
Hypothesis
The study aims to evaluate the effectiveness and safety of radiotherapy combined with nedaplatin and 5-FU for postoperative locoregional recurrent esophageal cancer.
Conclusion
Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment for postoperative locoregional recurrent esophageal cancer.
Supporting Evidence
- The 1-year overall survival rate was 60.6% and the 3-year rate was 56.3%.
- The median survival period was 39.0 months.
- Complete response was observed in 13.3% of patients and partial response in 60.0%.
- Grade 3 or higher leukocytopenia occurred in 30% of patients.
Takeaway
Doctors used radiation and two medicines to help patients with a type of cancer that came back after surgery, and it worked pretty well.
Methodology
The study involved a phase II trial with 30 patients receiving radiotherapy and chemotherapy consisting of nedaplatin and 5-FU.
Potential Biases
Potential biases include the exclusion of patients with hematogenous metastasis and the fact that all patients had squamous cell carcinoma.
Limitations
The observation period was too short to determine long-term results, and patients with performance status of 4 were excluded.
Participant Demographics
29 males and 1 female, median age 64 years (range 50-72).
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI = 42.4–78.8 for 1-year survival rate; 95% CI = 37.5–75.1 for 3-year survival rate.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website